BRIAN FRANCIS CHAPIN

TitleAssistant Professor
InstitutionMD Anderson
DepartmentUrology
Address1155 Pressler St
Houston TX 77030-3721
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Klaassen Z, Scarpato KR, Ristau BT, Stratton KL, Porten SP, Smaldone MC, Chapin BF, Psutka SP. Research highlights of the 2020 society of urologic oncology young urologic oncologists' program. Urol Oncol. 2021 Apr 12. PMID: 33858748.
      Citations:    Fields:    
    2. Ranasinghe W, Shapiro DD, Zhang M, Bathala T, Navone N, Thompson TC, Broom B, Aparicio A, Tu SM, Tang C, Davis JW, Pisters L, Chapin BF. Optimizing the diagnosis and management of ductal prostate cancer. Nat Rev Urol. 2021 Apr 06. PMID: 33824525.
      Citations:    Fields:    
    3. Oke O, Ranasinghe W, Tang C, Shaaban S, Xiao L, Reichard CA, Anscher MS, Chapin BF, Aparicio A. Impact of Definitive Local Therapy in Men with Primary Small Cell Prostate Carcinoma. Eur Urol. 2021 Apr 03. PMID: 33824032.
      Citations:    Fields:    
    4. Wilkins LJ, Tosoian JJ, Reichard CA, Sundi D, Ranasinghe W, Alam R, Schwen Z, Reddy C, Allaf M, Davis JW, Chapin BF, Ross AE, Klein EA, Nyame YA. Oncologic outcomes among Black and White men with grade group 4 or 5 (Gleason score 8-10) prostate cancer treated primarily by radical prostatectomy. Cancer. 2021 May 01; 127(9):1425-1431. PMID: 33721334.
      Citations:    Fields:    
    5. Baiomy A, Schellingerhout D, Chapin BF, Weinberg JS, Raza SM, Macapinlac H, Ravizzini G. Rate of incidental central nervous system meningioma detected in patients undergoing 18F-fluciclovine PET/CT imaging for evaluation of prostate cancer. Nucl Med Commun. 2021 Mar 12. PMID: 33741867.
      Citations:    Fields:    
    6. Altok M, Chapin BF, Matin SF, Achim MF, Gregg JR, Davis JW. Therapeutic Consequences of Omitting a Pelvic Lymph Node Dissection at Radical Prostatectomy when Grade and/or Stage Increase. Urology. 2021 Mar 05. PMID: 33676955.
      Citations:    Fields:    
    7. Gregg JR, Zhang X, Chapin BF, Ward JF, Kim J, Davis JW, Daniel CR. Adherence to the Mediterranean diet and grade group progression in localized prostate cancer: An active surveillance cohort. Cancer. 2021 Mar 01; 127(5):720-728. PMID: 33411364.
      Citations:    Fields:    
    8. Tang C, Lei X, Smith GL, Pan HY, Hoffman KE, Kumar R, Chapin BF, Shih YT, Frank SJ, Smith BD. Influence of Geography on Prostate Cancer Treatment. Int J Radiat Oncol Biol Phys. 2021 Apr 01; 109(5):1286-1295. PMID: 33316361.
      Citations:    Fields:    
    9. Ranasinghe W, Shapiro DD, Hwang H, Wang X, Reichard CA, Elsheshtawi M, Achim MF, Bathala T, Tang C, Aparicio A, Tu SM, Navone N, Thompson TC, Pisters L, Troncoso P, Davis JW, Chapin BF. Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional Therapies. Eur Urol. 2021 02; 79(2):298-306. PMID: 33279304.
      Citations: 1     Fields:    
    10. Wilkins LJ, Tosoian JJ, Sundi D, Ross AE, Grimberg D, Klein EA, Chapin BF, Nyame YA. Surgical management of high-risk, localized prostate cancer. Nat Rev Urol. 2020 Dec; 17(12):679-690. PMID: 33173205.
      Citations: 2     Fields:    
    11. Hussain M, Lin D, Saad F, Vapiwala N, Chapin BF, Sandler H, Evans CP, Carducci MA, Sachdev S. Newly Diagnosed High-Risk Prostate Cancer in an Era of Rapidly Evolving New Imaging: How Do We Treat? J Clin Oncol. 2021 Jan 01; 39(1):13-16. PMID: 33048621.
      Citations:    Fields:    
    12. Westerman ME, Tabakin AL, Sexton WJ, Chapin BF, Singer EA. Impact of CoVID-19 on resident and fellow education: Current guidance and future opportunities for urologic oncology training programs. Urol Oncol. 2020 Sep 30. PMID: 33160843.
      Citations:    Fields:    
    13. Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, Jarrard DF, Kibel AS, Morgan TM, Morgans AK, Oh WK, Resnick MJ, Zietman AL, Cookson MS. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II. J Urol. 2021 Jan; 205(1):22-29. PMID: 32960678.
      Citations:    Fields:    Translation:Humans
    14. Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, Jarrard DF, Kibel AS, Morgan TM, Morgans AK, Oh WK, Resnick MJ, Zietman AL, Cookson MS. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I. J Urol. 2021 Jan; 205(1):14-21. PMID: 32960679.
      Citations: 4     Fields:    Translation:Humans
    15. Shapiro DD, Gregg JR, Lim AH, Nogueras-González GM, Choi H, Kang HC, Inguillo IA, Chapin BF, Davis JW, Ward JF. Comparing confirmatory biopsy outcomes between MRI-targeted biopsy and standard systematic biopsy among men being enrolled in prostate cancer active surveillance. BJU Int. 2021 Mar; 127(3):340-348. PMID: 32357283.
      Citations:    Fields:    
    16. Ranasinghe WKB, Brooks NA, Elsheshtawi MA, Davis JW, Bathala TK, Tang C, Troncoso P, Aparicio A, Tu SM, Pisters LL, Chapin BF. Patterns of metastases of prostatic ductal adenocarcinoma. Cancer. 2020 08 15; 126(16):3667-3673. PMID: 32453443.
      Citations: 2     Fields:    Translation:Humans
    17. Chen B, Bathala TK, Xu G, Teyateeti A, Chapin BF, Tang C, Tu SM, Macapinlac HA, Lu Y. Comparison of Diagnostic Utility of Fluciclovine PET/CT Versus Pelvic Multiparametric MRI for Prostate Cancer in the Pelvis in the Setting of Rising PSA After Initial Treatment. Clin Nucl Med. 2020 May; 45(5):349-355. PMID: 31977495.
      Citations:    Fields:    Translation:Humans
    18. Abu-Gheida I, Bathala TK, Maldonado JA, Khan M, Anscher MS, Frank SJ, Choi S, Nguyen QN, Hoffman KE, McGuire SE, Kim M, Kuban DA, Aparicio A, Chapin BF, Tang C. Increased Frequency of Mesorectal and Perirectal LN Involvement in T4 Prostate Cancers. Int J Radiat Oncol Biol Phys. 2020 08 01; 107(5):982-985. PMID: 32353391.
      Citations:    Fields:    Translation:Humans
    19. Tang C, Lei X, Smith GL, Pan HY, Hess K, Chen A, Hoffman KE, Chapin BF, Kuban DA, Anscher M, Tina Shih YC, Frank SJ, Smith BD. Costs and Complications After a Diagnosis of Prostate Cancer Treated With Time-Efficient Modalities: An Analysis of National Medicare Data. Pract Radiat Oncol. 2020 Jul - Aug; 10(4):282-292. PMID: 32298794.
      Citations: 1     Fields:    Translation:Humans
    20. Ranasinghe W, Reichard CA, Nyame YA, Sundi D, Tosoian JJ, Wilkins L, Alam R, Achim MF, Wang X, Stephenson AJ, Klein EA, Ross AE, Allaf ME, Davis JW, Chapin BF. Downgrading from Biopsy Grade Group 4 Prostate Cancer in Patients Undergoing Radical Prostatectomy for High or Very High Risk Prostate Cancer. J Urol. 2020 10; 204(4):748-753. PMID: 32259468.
      Citations:    Fields:    Translation:Humans
    21. Ranasinghe W, Chapin BF, Kim IY, Sooriakumaran P, Lawrentschuk N. The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer. BJU Int. 2020 06; 125(6):792-800. PMID: 32176456.
      Citations: 2     Fields:    Translation:Humans
    22. Subudhi SK, Vence L, Zhao H, Blando J, Yadav SS, Xiong Q, Reuben A, Aparicio A, Corn PG, Chapin BF, Pisters LL, Troncoso P, Tidwell RS, Thall P, Wu CJ, Zhang J, Logothetis CL, Futreal A, Allison JP, Sharma P. Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Sci Transl Med. 2020 04 01; 12(537). PMID: 32238575.
      Citations: 14     Fields:    
    23. Bhargava P, Ravizzini G, Chapin BF, Kundra V. Imaging Biochemical Recurrence After Prostatectomy: Where Are We Headed? AJR Am J Roentgenol. 2020 06; 214(6):1248-1258. PMID: 32130049.
      Citations: 2     Fields:    Translation:Humans
    24. Bagley AF, Anscher MS, Choi S, Frank SJ, Hoffman KE, Kuban DA, McGuire SE, Nguyen QN, Chapin B, Aparicio A, Pezzi TA, Smith GL, Smith BD, Hess K, Tang C. Association of Sociodemographic and Health-Related Factors With Receipt of Nondefinitive Therapy Among Younger Men With High-Risk Prostate Cancer. JAMA Netw Open. 2020 03 02; 3(3):e201255. PMID: 32191331.
      Citations: 2     Fields:    Translation:Humans
    25. Surasi DSS, Chapin B, Tang C, Ravizzini G, Bathala TK. Imaging and Management of Prostate Cancer. Semin Ultrasound CT MR. 2020 Apr; 41(2):207-221. PMID: 32446432.
      Citations:    Fields:    
    26. Gregg JR, Davis JW, Reichard C, Wang X, Achim M, Chapin BF, Pisters L, Pettaway C, Ward JF, Choi S, Nguyen QN, Kuban D, Babaian R, Troncoso P, Madsen LT, Logothetis C, Kim J. Determining Clinically Based Factors Associated With Reclassification in the Pre-MRI Era using a Large Prospective Active Surveillance Cohort. Urology. 2020 Apr; 138:91-97. PMID: 31899230.
      Citations:    Fields:    
    27. Tang C, Hoffman KE, Allen PK, Gabel M, Schreiber D, Choi S, Chapin BF, Nguyen QN, Davis JW, Corn P, Logothetis C, Ward J, Frank SJ, Navai N, McGuire SE, Anscher M, Pisters L, Pettaway CA, Kumar R, Linson P, Tripuraneni P, Tomaszewski JJ, Patel AB, Augspurger M, Kuban DA. Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends. Cancer. 2020 02 01; 126(3):506-514. PMID: 31742674.
      Citations: 3     Fields:    Translation:Humans
    28. Baack Kukreja J, Bathala TK, Reichard CA, Troncoso P, Delacroix S, Davies B, Eggener S, Smaldone M, Minhaj Siddiqui M, Tollefson M, Chapin BF. Impact of preoperative prostate magnetic resonance imaging on the surgical management of high-risk prostate cancer. Prostate Cancer Prostatic Dis. 2020 03; 23(1):172-178. PMID: 31501508.
      Citations:    Fields:    Translation:Humans
    29. Reichard CA, Chapin BF. Editorial Comment. Urology. 2019 09; 131:174. PMID: 31451157.
      Citations:    Fields:    Translation:Humans
    30. Ranasinghe WKB, Reichard CA, Bathala T, Chapin BF. Management of cT4 Prostate Cancer. Eur Urol Focus. 2020 03 15; 6(2):221-226. PMID: 31266732.
      Citations: 2     Fields:    Translation:Humans
    31. Ranasinghe WKB, Reichard CA, Chapin BF. Treatment of the Primary Tumor in Metastatic Hormone-sensitive Prostate Cancer: Not Yet Ready for Prime Time as the Standard of Care. Eur Urol. 2019 Nov; 76(5):543-545. PMID: 31248604.
      Citations:    Fields:    Translation:Humans
    32. Reichard CA, Hoffman KE, Tang C, Williams SB, Allen PK, Achim MF, Kuban DA, Chapin BF. Radical prostatectomy or radiotherapy for high- and very high-risk prostate cancer: a multidisciplinary prostate cancer clinic experience of patients eligible for either treatment. BJU Int. 2019 11; 124(5):811-819. PMID: 31009137.
      Citations: 7     Fields:    Translation:Humans
    33. Reichard CA, Kukreja J, Gregg JR, Bathala TK, Achim MF, Wang X, Davis JW, Nguyen QN, Chapin BF. Prediction of Organ-confined Disease in High- and Very-high-risk Prostate Cancer Patients Staged with Magnetic Resonance Imaging: Implications for Clinical Trial Design. Eur Urol Focus. 2021 Jan; 7(1):71-77. PMID: 31076357.
      Citations:    Fields:    
    34. Chapin BF. Clinical Trials in Urology. Urol Oncol. 2019 05; 37(5):303-304. PMID: 30904395.
      Citations:    Fields:    Translation:Humans
    35. Sundi D, Chapin BF. Very-high-risk (VHR) localized prostate cancer: an indication for multimodal therapy. Oncotarget. 2019 Mar 08; 10(20):1870-1871. PMID: 30956769.
      Citations:    Fields:    
    36. Reichard CA, Nyame YA, Sundi D, Tosoian J, Wilkins L, Alam R, Achim MF, Wang X, Stephenson AJ, Klein EA, Ross AE, Davis JW, Chapin BF. Does time from diagnosis to treatment of high- or very-high-risk prostate cancer affect outcome? BJU Int. 2019 08; 124(2):282-289. PMID: 30653804.
      Citations: 4     Fields:    Translation:Humans
    37. Gregg JR, Lopez DS, Reichard C, Zheng J, Wu W, Ye Y, Chapin B, Kim J, Daniel CR, Davis J. Coffee, Caffeine Metabolism Genotype and Disease Progression in Patients with Localized Prostate Cancer Managed with Active Surveillance. J Urol. 2019 02; 201(2):308-314. PMID: 30179617.
      Citations:    Fields:    Translation:Humans
    38. Gregg JR, Zheng J, Lopez DS, Reichard C, Browman G, Chapin B, Kim J, Davis J, Daniel CR. Diet quality and Gleason grade progression among localised prostate cancer patients on active surveillance. Br J Cancer. 2019 02; 120(4):466-471. PMID: 30679782.
      Citations: 1     Fields:    Translation:Humans
    39. Truong M, Baack Kukreja JE, Rais-Bahrami S, Barashi NS, Wang B, Nuffer Z, Park JH, Lam K, Frye TP, Nix JW, Thomas JV, Feng C, Chapin BF, Davis JW, Hollenberg G, Oto A, Eggener SE, Joseph JV, Weinberg E, Messing EM. Multi-institutional Clinical Tool for Predicting High-risk Lesions on 3Tesla Multiparametric Prostate Magnetic Resonance Imaging. Eur Urol Oncol. 2019 05; 2(3):257-264. PMID: 31200839.
      Citations: 1     Fields:    Translation:Humans
    40. Patel DN, Chapin BF, Freedland SJ. Response to Editorial Comment to Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital. Int J Urol. 2018 12; 25(12):1005. PMID: 30458585.
      Citations:    Fields:    Translation:Humans
    41. Sundi D, Tosoian JJ, Nyame YA, Alam R, Achim M, Reichard CA, Li J, Wilkins L, Schwen Z, Han M, Davis JW, Klein EA, Schaeffer EM, Stephenson AJ, Ross AE, Chapin BF. Outcomes of very high-risk prostate cancer after radical prostatectomy: Validation study from 3 centers. Cancer. 2019 02 01; 125(3):391-397. PMID: 30423193.
      Citations: 3     Fields:    Translation:Humans
    42. Patel DN, Jha S, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Chapin BF, Freedland SJ. Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital. Int J Urol. 2018 12; 25(12):998-1004. PMID: 30253446.
      Citations: 1     Fields:    Translation:Humans
    43. Jaber Y, Reichard CA, Chapin BF. Emerging role of cytoreductive prostatectomy in patients with metastatic disease. Transl Androl Urol. 2018 Sep; 7(Suppl 4):S505-S513. PMID: 30363448.
      Citations: 2     
    44. Altok M, Kim B, Patel BB, Shih YT, Ward JF, McRae SE, Chapin BF, Pisters LL, Pettaway CA, Kim J, Demirel HC, Davis JW. Cost and efficacy comparison of five prostate biopsy modalities: a platform for integrating cost into novel-platform comparative research. Prostate Cancer Prostatic Dis. 2018 11; 21(4):524-532. PMID: 29988098.
      Citations: 6     Fields:    Translation:Humans
    45. Cartapatti M, Machado RD, Muller RL, Magnabosco WJ, Santos AC, Chapin BF, Melani A, Talvane A, Tobias-Machado M, Faria EF. Synchronous abdominal tumors: is combined laparoscopic surgery in a single approach a safe option? Int Braz J Urol. 2018 May-Jun; 44(3):483-490. PMID: 29219275.
      Citations: 2     Fields:    Translation:Humans
    46. Reichard CA, Gregg JR, Achim MF, Aparicio AM, Pettaway CA, Pisters LL, Ward JF, Davis JW, Chapin BF. Radical Prostatectomy in Metastatic Castration-resistant Prostate Cancer: Feasibility, Safety, and Quality of Life Outcomes. Eur Urol. 2018 08; 74(2):140-143. PMID: 29656854.
      Citations: 3     Fields:    Translation:Humans
    47. Altok M, Babaian K, Achim MF, Achim GC, Troncoso P, Matin SF, Chapin BF, Davis JW. Surgeon-led prostate cancer lymph node staging: pathological outcomes stratified by robot-assisted dissection templates and patient selection. BJU Int. 2018 07; 122(1):66-75. PMID: 29446205.
      Citations: 3     Fields:    Translation:Humans
    48. Reichard C, Chapin BF. Can Focal Therapy Replace Radical Therapy for Prostate Cancer? Against Focal Therapy. Eur Urol Focus. 2017 12; 3(6):524-525. PMID: 29439879.
      Citations:    Fields:    Translation:Humans
    49. Kukreja JB, Thompson IM, Chapin BF. Organizing a clinical trial for the new investigator. Urol Oncol. 2019 05; 37(5):336-339. PMID: 29395953.
      Citations:    Fields:    Translation:Humans
    50. Chapin BF, Nguyen JN, Achim MF, Navai N, Williams SB, Prokhorova IN, Wang X, Tapia EMLN, Davis JW, Troncoso P. Positive margin length and highest Gleason grade of tumor at the margin predict for biochemical recurrence after radical prostatectomy in patients with organ-confined prostate cancer. Prostate Cancer Prostatic Dis. 2018 06; 21(2):221-227. PMID: 29230008.
      Citations: 1     Fields:    Translation:Humans
    51. Li R, Ravizzini GC, Gorin MA, Maurer T, Eiber M, Cooperberg MR, Alemozzaffar M, Tollefson MK, Delacroix SE, Chapin BF. The use of PET/CT in prostate cancer. Prostate Cancer Prostatic Dis. 2018 04; 21(1):4-21. PMID: 29230009.
      Citations: 18     Fields:    Translation:Humans
    52. Chapin BF, Bellmunt J. 'Working toward understanding oligo and polymetastatic prostate cancer'. Curr Opin Urol. 2017 11; 27(6):532. PMID: 28922341.
      Citations:    Fields:    Translation:Humans
    53. Blanchard P, Davis JW, Frank SJ, Kim J, Pettaway CA, Pugh TJ, Pisters LL, Ward JF, Choi S, Chapin BF, Hoffman K, Navai N, Achim M, McGuire SE, Matin SF, Nguyen Q, Mahmood U, Graber WJ, Chen HC, Wang X, Kuban DA. Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort. BJU Int. 2018 04; 121(4):540-548. PMID: 28941030.
      Citations: 4     Fields:    Translation:Humans
    54. Altok M, Achim MF, Matin SF, Pettaway CA, Chapin BF, Davis JW. A decade of robot-assisted radical prostatectomy training: Time-based metrics and qualitative grading for fellows and residents. Urol Oncol. 2018 01; 36(1):13.e19-13.e25. PMID: 28964658.
      Citations:    Fields:    Translation:Humans
    55. Basourakos SP, Davis JW, Chapin BF, Ward JF, Pettaway CA, Pisters LL, Navai N, Achim MF, Wang X, Chen HC, Choi S, Kuban D, Troncoso P, Hanash S, Thompson TC, Kim J. Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer. BJU Int. 2018 01; 121(1):69-76. PMID: 28710901.
      Citations: 5     Fields:    Translation:Humans
    56. Reichard CA, Chapin BF. Local Therapy for Disseminated Prostate Cancer: Improved Outcomes or Biased Confounders? Eur Urol. 2017 09; 72(3):352-353. PMID: 28552614.
      Citations:    Fields:    Translation:Humans
    57. Metcalfe MJ, Chapin BF. Editorial Comment. Urology. 2017 08; 106:151-152. PMID: 28550942.
      Citations:    Fields:    
    58. Metcalfe MJ, Smaldone MC, Lin DW, Aparicio AM, Chapin BF. Role of radical prostatectomy in metastatic prostate cancer: A review. Urol Oncol. 2017 04; 35(4):125-134. PMID: 28190749.
      Citations: 5     Fields:    Translation:Humans
    59. Williams SB, Huo J, Chamie K, Smaldone MC, Kosarek CD, Fang JE, Ynalvez LA, Kim SP, Hoffman KE, Giordano SH, Chapin BF. Discerning the survival advantage among patients with prostate cancer who undergo radical prostatectomy or radiotherapy: The limitations of cancer registry data. Cancer. 2017 05 01; 123(9):1617-1624. PMID: 28099688.
      Citations: 5     Fields:    Translation:Humans
    60. Williams SB, Chapin BF. Patterns of Care for Prostate Cancer Patients: Predictors of Care, But For Whom? Eur Urol. 2017 05; 71(5):738-739. PMID: 27815080.
      Citations:    Fields:    Translation:Humans
    61. Bayne CE, Williams -B, Chapin BF. Reply to Lu Yang, Shi Qiu and Qiang Wei's Letter to the Editor re: Christopher E. Bayne, Stephen B. Williams, Matthew R. Cooperberg, et al. Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives. Eur Urol 2016;69:775-87. Eur Urol. 2017 02; 71(2):e51. PMID: 27461403.
      Citations:    Fields:    Translation:Humans
    62. Rusthoven CG, Jones BL, Flaig TW, Crawford ED, Koshy M, Sher DJ, Mahmood U, Chen RC, Chapin BF, Kavanagh BD, Pugh TJ. Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer. J Clin Oncol. 2016 08 20; 34(24):2835-42. PMID: 27325855.
      Citations: 49     Fields:    Translation:Humans
    63. Ristau BT, Cahn D, Uzzo RG, Chapin BF, Smaldone MC. The role of radical prostatectomy in high-risk localized, node-positive and metastatic prostate cancer. Future Oncol. 2016 Mar; 12(5):687-99. PMID: 26839141.
      Citations: 3     Fields:    Translation:Humans
    64. Chapin BF. Optimal management of prostate cancer with lethal biology--state-of-the-art local therapy. Asian J Androl. 2015 Nov-Dec; 17(6):888-91. PMID: 26178396.
      Citations: 1     Fields:    Translation:Humans
    65. Williams SB, Davis JW, Wang X, Achim MF, Zurita-Saavedra A, Matin SF, Pisters LL, Ward JF, Pettaway CA, Chapin BF. Neoadjuvant Systemic Therapy Before Radical Prostatectomy in High-Risk Prostate Cancer Does Not Increase Surgical Morbidity: Contemporary Results Using the Clavien System. Clin Genitourin Cancer. 2016 Apr; 14(2):130-8. PMID: 26558524.
      Citations: 3     Fields:    Translation:Humans
    66. Davis JW, Ward JF, Pettaway CA, Wang X, Kuban D, Frank SJ, Lee AK, Pisters LL, Matin SF, Shah JB, Karam JA, Chapin BF, Papadopoulos JN, Achim M, Hoffman KE, Pugh TJ, Choi S, Troncoso P, Logothetis CJ, Kim J. Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int. 2016 07; 118(1):68-76. PMID: 26059275.
      Citations: 14     Fields:    Translation:Humans
    67. Faria EF, Chapin BF, Muller RL, Machado RD, Reis RB, Matin SF. Radical Prostatectomy for Locally Advanced Prostate Cancer: Current Status. Urology. 2015 Jul; 86(1):10-5. PMID: 26048432.
      Citations: 12     Fields:    Translation:Humans
    68. Bayne CE, Williams SB, Cooperberg MR, Gleave ME, Graefen M, Montorsi F, Novara G, Smaldone MC, Sooriakumaran P, Wiklund PN, Chapin BF. Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives. Eur Urol. 2016 05; 69(5):775-87. PMID: 26003223.
      Citations: 13     Fields:    Translation:Humans
    69. Chapin BF, McGuire SE, Aparicio A. Is treatment of the primary tumor in metastatic prostate cancer justified? Eur Urol. 2014 Jun; 65(6):1067-8. PMID: 24411278.
      Citations: 2     Fields:    Translation:Humans
    70. Wirth GJ, Psutka SP, Chapin BF, Wu S, Wu CL, Dahl DM. Midterm oncological outcomes of laparoscopic vs open radical prostatectomy (RP). BJU Int. 2013 Jul; 112(2):190-7. PMID: 23601185.
      Citations:    Fields:    Translation:Humans
    71. Delacroix SE, Chapin BF, Wood CG. The role of lymph node dissection in renal cell carcinoma. Urol Clin North Am. 2011 Nov; 38(4):419-28, vi. PMID: 22045173.
      Citations: 3     Fields:    Translation:Humans
    72. Delacroix SE, Chapin BF, Chen JJ, Nogueras-Gonzalez GM, Tamboli P, Matin SF, Wood CG. Can a durable disease-free survival be achieved with surgical resection in patients with pathological node positive renal cell carcinoma? J Urol. 2011 Oct; 186(4):1236-41. PMID: 21849197.
      Citations: 13     Fields:    Translation:Humans
    73. Chapin BF, Delacroix SE, Wood CG. Renal cell carcinoma: what the surgeon and treating physician need to know. AJR Am J Roentgenol. 2011 Jun; 196(6):1255-62. PMID: 21606286.
      Citations: 2     Fields:    Translation:Humans
    74. Chapin BF, Delacroix SE, Culp SH, Nogueras Gonzalez GM, Tannir NM, Jonasch E, Tamboli P, Wood CG. Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma. Eur Urol. 2011 Nov; 60(5):964-71. PMID: 21621907.
      Citations: 25     Fields:    Translation:Humans
    75. Chapin BF, Delacroix SE, Wood CG. The role of lymph node dissection in renal cell carcinoma. Int J Clin Oncol. 2011 Jun; 16(3):186-94. PMID: 21523561.
      Citations:    Fields:    Translation:Humans
    76. Chapin BF, Wood CG. The RENAL nephrometry nomogram: statistically significant, but is it clinically relevant? Eur Urol. 2011 Aug; 60(2):249-51; discussion 251-2. PMID: 21514040.
      Citations: 4     Fields:    Translation:Humans
    77. Cost NG, Delacroix SE, Sleeper JP, Smith PJ, Youssef RF, Chapin BF, Karam JA, Culp S, Abel EJ, Brugarolas J, Raj GV, Sagalowsky AI, Wood CG, Margulis V. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur Urol. 2011 Jun; 59(6):912-8. PMID: 21367518.
      Citations: 54     Fields:    Translation:Humans
    78. Eisner BH, Feldman AS, Chapin BF, Dretler SP. "Blind coning"--using the Stone Cone for removal of intramural ureteral calculi. Urology. 2007 Apr; 69(4):773-5. PMID: 17445670.
      Citations:    Fields:    Translation:Humans
    79. Oyelese Y, Tchabo JG, Chapin B, Nair A, Hanson P, McLaren R. Conservative management of uterine rupture diagnosed prenatally on the basis of sonography. J Ultrasound Med. 2003 Sep; 22(9):977-80. PMID: 14510271.
      Citations: 1     Fields:    Translation:Humans
    80. Cytoreductive nephrectomy. 109-122.
    81. Patterns of Care for Prostate Cancer Patients. European Urology.
    82. Optimal management of prostate cancer with lethal biology - State-of-the-art local therapy. Asian Journal of Andrology. 17:888-891.
    83. Treatment of the Primary Tumor in Metastatic Prostate Cancer. European Urology.
    84. The role of radical prostatectomy in high-risk localized, node-positive and metastatic prostate cancer. Future Oncology. 12:687-699.
    85. Reply to Lu Yang, Shi Qiu and Qiang Wei Letter to the Editor re. European Urology. 71:e51.
    86. Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer. Journal of Clinical Oncology. 34:2835-2842.
    87. Neoadjuvant Systemic Therapy before Radical Prostatectomy in High-Risk Prostate Cancer Does Not Increase Surgical Morbidity. Clinical Genitourinary Cancer. 14:130-138.
    CHAPIN's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (184)
    Explore
    _
    Co-Authors (47)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _